exRNAdisease

General Information

Database ID:

exR0088562

RNA Name:

hsa-miR-449b-5p

RNA Type:

miRNA

Chromosome:

chr5

Starnd:

Coordinate:

Start Site(bp):

55170706

End Site(bp):

55170727

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
MID1	chrX	10445310	10833654	-
JPH1	chr8	74234700	74321540	-
TAOK1	chr17	29390464	29551904	+
DEDD2	chr19	42198598	42220140	-
PTPRJ	chr11	47980558	48170841	+
GNA12	chr7	2728105	2844308	-
HNRNPUL1	chr19	41262496	41307787	+
ZNF623	chr8	143636013	143656418	+
SUPT6H	chr17	28662198	28702679	+
NCOR1	chr17	16029157	16218185	-
IGSF3	chr1	116574399	116667755	-
ANKRD52	chr12	56237807	56258384	-
ESS2	chr22	19130279	19144684	-
TNRC6B	chr22	40044817	40335808	+
ZIC5	chr13	99962964	99971909	-
JRK	chr8	142657460	142681968	-
GATAD2B	chr1	153789030	153923360	-
ATXN7L3	chr17	44191805	44200113	-
AMER1	chrX	64185117	64205708	-
STK38L	chr12	27243968	27325959	+
SH3PXD2A	chr10	103594027	103855543	-
CD151	chr11	832887	839831	+
NPTX1	chr17	80466834	80477843	-
MYCN	chr2	15940550	15947007	+
NDST1	chr5	150485818	150558211	+
TMEM109	chr11	60914158	60923443	+
ERGIC1	chr5	172834251	172952683	+
RTL8B	chrX	135020513	135022542	-
FGFRL1	chr4	1009936	1026898	+
IL2RB	chr22	37125843	37175054	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001723	chr7	91924202	91948826	+
hsa_circ_0001495	chr5	68470703	68471364	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0000038	chr1	28800065	28802803	+
hsa_circ_0001865	chr9	86292641	86293514	-
hsa_circ_0001146	chr20	34241449	34246936	-
hsa_circ_0001164	chr20	45891031	45923523	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC018521.1	chr17	47945424	47981736	+
AC116913.1	chr15	66488658	66492109	-
HCG18	chr6	30286690	30327382	-
KCNQ1OT1	chr11	2608328	2699994	-
LINC00665	chr19	36313067	36331770	-
NEAT1	chr11	65422774	65445540	+
SNHG7	chr9	136721366	136728184	-
TERC	chr3	169764520	169765060	-
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.